FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases

Annals of Oncology

Volumn 16, Issue 3, 2005, Pages 473-480

  Beal, K P ^a   Yeung, H W ^a   Yahalom, J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

MALT lymphoma; PET scan

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; MALE; MEDICAL INFORMATION; MEDICAL RECORD; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 16244400833     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi093     Document Type: Article

References (24)

1. Talbot JN, Haioun C, Rain JD et al. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001; 38: 193-221.
2. Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
3. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225-1231.
4. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.
5. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
6. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
7. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT lymphomas. Hematology (Am Soc Hematol Educ Program) 2001; 241-258.
8. Zucca E, Bertoni F, Cavalli F. Pathogenesis and treatment of extranodal lymphomas: the fascinating model of mucosa-associated lymphoid tissue lymphoma. Haematologica 2003; 88: 841-844.
9. Zucca E, Conconi A, Cavalli F et al. Treatment of extranodal lymphomas. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue MALT lymphomas. Best Pract Res Clin Haematol 2002; 15: 533-547.
10. Raderer M, Vorbeck F, Formanek M et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000; 83: 454-457.
11. Erdi YE, Rosenzweig K, Erdi AK et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002; 62: 51-60.
12. Lapela M, Leskinen S, Minn HR et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
13. Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
14. Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 262-268.
15. Hoffmann M, Kletter K, Diemling M et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10: 1185-1189.
16. Hoffmann M, Kletter K, Becherer A et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64: 336-340.
17. Sun SS, Chuang FJ, Kao CH. Mucosa-associated lymphoid tissue lymphoma of the lung detected with Ga-67 SPECT imaging. Clin Nucl Med 2002; 27: 604.
18. Hara M, Sugie C, Tohyama J et al. Increased (18)fluorodeoxyglucose accumulation in mucosa-associated lymphoid tissue-type lymphoma of the lung. J Thorac Imaging 2002; 17: 160-162.
19. Pieterman RM, van Putten JW, Meuzelaar JJ et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: 254-261.
20. Vansteenkiste JF, Stroobants SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am 2004; 18: 269-288.
21. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507.
22. Fiche M, Caprons F, Berger F et al. Primary pulmonary non-Hodgkin's lymphomas. Histopathology 1995; 26: 529-537.
23. Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20: 750-762.
24. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: Current status. Oncologist 2003; 8: 438-447.